Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes
Abstract Purpose To report data on the real-world effectiveness and safety of injectable (IS) and oral (OS) therapies in obese or overweight diabetes (T2DM) patients on glycometabolic control, weight loss (WL) and weight maintenance after the use of semaglutide. Methods 175 subjects with obesity or ...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Eating and Weight Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40519-024-01711-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841545084720381952 |
|---|---|
| author | Michela Del Prete Lidia Gavazzi Olga Eugenia Disoteo Federico Vignati Gianleone Di Sacco Fabrizio Muratori |
| author_facet | Michela Del Prete Lidia Gavazzi Olga Eugenia Disoteo Federico Vignati Gianleone Di Sacco Fabrizio Muratori |
| author_sort | Michela Del Prete |
| collection | DOAJ |
| description | Abstract Purpose To report data on the real-world effectiveness and safety of injectable (IS) and oral (OS) therapies in obese or overweight diabetes (T2DM) patients on glycometabolic control, weight loss (WL) and weight maintenance after the use of semaglutide. Methods 175 subjects with obesity or overweight and T2DM were retrospectively assessed. Of these, 129 (75F, 54 M; mean age 61.2 ± 9.8 years) patients were treated with IS and 46 (24F, 22 M; mean age 65.7 ± 12.8 years) with OS for T2DM and WL. At baseline, mean weight (mW) was 101.8 ± 24.6 kg and 95.2 ± 15.0 kg; mean body mass index (mBMI) was 36.7 ± 8.7 kg/m2 and 34.3 ± 5.3 kg/m2. Results After 6 months, in the IS group, 127 patients had a mW and mBMI reduction of − 10.4 ± 8.1 kg and − 3.9 ± 3.0 kg/m2. 46 patients in the OS group had a mW and mBMI reduction of − 6.7 ± 5.3 kg and − 2.6 ± 2.1 kg/m2. After 12 months, 102 patients in the IS group achieved a mW and mBMI reduction of − 9.3 ± 7.5 kg and − 3.4 ± 2.6 kg/m2. 44 patients in the OS group of treatment had a mW and mBMI reduction of − 10.7 ± 6.5 kg and − 3.9 ± 2.4 kg/m2. After 24 months, 92 patients in the IS group of therapy achieved a mW and mBMI reduction of − 15.9 ± 11.4 kg and − 5.8 ± 3.7 kg/m2. There was a mean percentage reduction of glycated hemoglobin (HBA1C) of − 1.9 ± 1.4%, − 1.5 ± 1.9%, and − 1.5 ± 1.7% after 6, 12 and 24 months in the IS group. In the OS group there was a mean reduction of − 1.5 ± 1.6% after 6 months and of − 0.8 ± 0.6% after 12 months of therapy. Conclusions Semaglutide induces WL maintenance after 12 and 24 months of treatment. Our results show a comparable effectiveness of IS and OS in T2DM patients with obesity or overweight. IS and OS treatment provide significant WL that allows reaching the glycometabolic therapeutic goal in a short time. Level of Evidence Level II |
| format | Article |
| id | doaj-art-d96b78d014cb4a01b1362541c91f52f2 |
| institution | Kabale University |
| issn | 1590-1262 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Eating and Weight Disorders |
| spelling | doaj-art-d96b78d014cb4a01b1362541c91f52f22025-01-12T12:05:06ZengSpringerEating and Weight Disorders1590-12622025-01-013011510.1007/s40519-024-01711-2Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetesMichela Del Prete0Lidia Gavazzi1Olga Eugenia Disoteo2Federico Vignati3Gianleone Di Sacco4Fabrizio Muratori5Division of Endocrinology, Diabetology and Clinical Nutrition, Sant’Anna Hospital – ASST LarianaDivision of Endocrinology, Diabetology and Clinical Nutrition, Sant’Anna Hospital – ASST LarianaDivision of Endocrinology, Diabetology and Clinical Nutrition, Sant’Anna Hospital – ASST LarianaDivision of Endocrinology, Diabetology and Clinical Nutrition, Sant’Anna Hospital – ASST LarianaDivision of Endocrinology, Diabetology and Clinical Nutrition, Sant’Anna Hospital – ASST LarianaDivision of Endocrinology, Diabetology and Clinical Nutrition, Sant’Anna Hospital – ASST LarianaAbstract Purpose To report data on the real-world effectiveness and safety of injectable (IS) and oral (OS) therapies in obese or overweight diabetes (T2DM) patients on glycometabolic control, weight loss (WL) and weight maintenance after the use of semaglutide. Methods 175 subjects with obesity or overweight and T2DM were retrospectively assessed. Of these, 129 (75F, 54 M; mean age 61.2 ± 9.8 years) patients were treated with IS and 46 (24F, 22 M; mean age 65.7 ± 12.8 years) with OS for T2DM and WL. At baseline, mean weight (mW) was 101.8 ± 24.6 kg and 95.2 ± 15.0 kg; mean body mass index (mBMI) was 36.7 ± 8.7 kg/m2 and 34.3 ± 5.3 kg/m2. Results After 6 months, in the IS group, 127 patients had a mW and mBMI reduction of − 10.4 ± 8.1 kg and − 3.9 ± 3.0 kg/m2. 46 patients in the OS group had a mW and mBMI reduction of − 6.7 ± 5.3 kg and − 2.6 ± 2.1 kg/m2. After 12 months, 102 patients in the IS group achieved a mW and mBMI reduction of − 9.3 ± 7.5 kg and − 3.4 ± 2.6 kg/m2. 44 patients in the OS group of treatment had a mW and mBMI reduction of − 10.7 ± 6.5 kg and − 3.9 ± 2.4 kg/m2. After 24 months, 92 patients in the IS group of therapy achieved a mW and mBMI reduction of − 15.9 ± 11.4 kg and − 5.8 ± 3.7 kg/m2. There was a mean percentage reduction of glycated hemoglobin (HBA1C) of − 1.9 ± 1.4%, − 1.5 ± 1.9%, and − 1.5 ± 1.7% after 6, 12 and 24 months in the IS group. In the OS group there was a mean reduction of − 1.5 ± 1.6% after 6 months and of − 0.8 ± 0.6% after 12 months of therapy. Conclusions Semaglutide induces WL maintenance after 12 and 24 months of treatment. Our results show a comparable effectiveness of IS and OS in T2DM patients with obesity or overweight. IS and OS treatment provide significant WL that allows reaching the glycometabolic therapeutic goal in a short time. Level of Evidence Level IIhttps://doi.org/10.1007/s40519-024-01711-2SemaglutideOverweightObesityContinuing weight lossDiabetes |
| spellingShingle | Michela Del Prete Lidia Gavazzi Olga Eugenia Disoteo Federico Vignati Gianleone Di Sacco Fabrizio Muratori Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes Eating and Weight Disorders Semaglutide Overweight Obesity Continuing weight loss Diabetes |
| title | Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes |
| title_full | Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes |
| title_fullStr | Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes |
| title_full_unstemmed | Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes |
| title_short | Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes |
| title_sort | real world effectiveness of semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes |
| topic | Semaglutide Overweight Obesity Continuing weight loss Diabetes |
| url | https://doi.org/10.1007/s40519-024-01711-2 |
| work_keys_str_mv | AT micheladelprete realworldeffectivenessofsemaglutidetreatmentonweightlossmaintenanceafterweightlossinpatientswithobesityoroverweightanddiabetes AT lidiagavazzi realworldeffectivenessofsemaglutidetreatmentonweightlossmaintenanceafterweightlossinpatientswithobesityoroverweightanddiabetes AT olgaeugeniadisoteo realworldeffectivenessofsemaglutidetreatmentonweightlossmaintenanceafterweightlossinpatientswithobesityoroverweightanddiabetes AT federicovignati realworldeffectivenessofsemaglutidetreatmentonweightlossmaintenanceafterweightlossinpatientswithobesityoroverweightanddiabetes AT gianleonedisacco realworldeffectivenessofsemaglutidetreatmentonweightlossmaintenanceafterweightlossinpatientswithobesityoroverweightanddiabetes AT fabriziomuratori realworldeffectivenessofsemaglutidetreatmentonweightlossmaintenanceafterweightlossinpatientswithobesityoroverweightanddiabetes |